United States News All stories

TE Connectivity (NYSE:TEL) announced Wednesday that its board of directors has declared a regular quarterly cash dividend of $0.78 per ordinary share.

Taiwan Semiconductor Manufacturing Company (NYSE:TSM) posted record consolidated revenue for May 2026, setting a new single-month high as global technology enterprises continue to aggressively ramp up hardware procurement for artificial intelligence applications.

Yuanbao (NASDAQ:YB), a technology-driven online insurance distributor in China, reported a 31.4 percent surge in net income for the first quarter of 2026, driven by robust top-line momentum across its digital platform.

ChipMOS TECHNOLOGIES (NASDAQ:IMOS) reported a 17.7 percent year-over-year increase in its unaudited consolidated revenue for May 2026, capitalizing on an artificial intelligence sector expansion that continues to outpace broader manufacturing capacity.

Cango (NYSE:CANG) published its operational update for May 2026, detailing the capacity metrics of its global digital asset mining network as the company continues to transition toward an integrated energy and artificial intelligence computing platform.

Cheetah Mobile (NYSE:CMCM) reported a significantly narrowed net loss for the first quarter of 2026, capitalizing on an aggressive operational pivot that generated a triple-digit surge within its commercial robotics business alongside steady growth in cloud infrastructure.

Crude oil prices remained tightly range-bound on Wednesday morning as escalating military hostilities between the United States and Iran counterbalanced supportive domestic inventory data. Traders are weighing the structural threat of a prolonged Middle East chokepoint shutdown against slowing global demand signals.

Meta Platforms (NASDAQ:META) is partnering with Reliance Industries to build its first artificial intelligence data center in India, joining a massive wave of global technology capital flowing into the South Asian country’s computing infrastructure.

Eli Lilly (NYSE:LLY) secured U.S. regulatory approval for a less-frequent dosing regimen of its eczema treatment Ebglyss, providing patients with a maintenance option that significantly reduces the annual injection burden.

Rafael Holdings (NYSE:RFL) announced that the last patient has completed the final 96-week study visit in its pivotal Phase 3 TransportNPC™ trial evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C (NPC).

Lakeland Industries, operating as Lakeland Fire + Safety (NASDAQ:LAKE), reported a return to net profitability for the fiscal first quarter of 2027, driven by robust expansion within its core fire services segment and structural optimization of its product portfolio.

European Union antitrust regulators ordered Meta Platforms (NASDAQ:META) to grant competing artificial intelligence chatbots free access to its WhatsApp messaging service, utilizing emergency interim powers for the first time in 17 years to protect startup developers while a broader market-power investigation proceeds.

Tango Therapeutics (NASDAQ:TNGX) shares climbed to a record high after the company unveiled initial clinical data showing that its experimental oncology asset, vopimetostat, shrunk tumors in nearly all evaluated pancreatic cancer patients when combined with Revolution Medicines' daraxonrasib.

Perma-Pipe International Holdings (NASDAQ:PPIH) reported an expansion in top-line revenue for the first quarter of fiscal year 2026, driven by sustained industrial demand across its primary geographic footprints, though near-term factory start-up friction and heightened regulatory compliance outlays compressed bottom-line margins.

Teleflex (NYSE:TFX) announced positive four-year follow-up data from its First-in-Human BIOMAG-I clinical trial, reinforcing the long-term safety and performance stability of its third-generation Freesolve Resorbable Magnesium Scaffold.

Vivakor (NASDAQ:VIVK) reported a narrower net loss and significantly stronger gross margins for the first quarter of 2026, signaling early progress in the company’s ongoing pivot toward its higher-margin midstream and logistics operations.

Cartesian Therapeutics (NASDAQ:RNAC) announced a strategic licensing agreement with WestGene Biopharma to co-develop innovative in vivo mRNA chimeric antigen receptor T-cell (CAR-T) therapies, marking a significant expansion of its clinical efforts to target severe autoimmune conditions.

BitFuFu (NASDAQ:FUFU) reported a 22.1% month-over-month increase in its unaudited Bitcoin production for May 2026, driven by a deliberate pivot toward its proprietary self-mining business and stabilized infrastructure conditions across its international footprint.

Aditxt (NASDAQ:ADTX) announced that its wholly owned subsidiary, Ignite Proteomics, has entered into a definitive business combination agreement with a strategic counterparty to transition the functional proteomics firm into an independent, publicly traded corporation.

OFS Credit Company (NASDAQ:OCCI) reported a contraction in its net asset value and a decline in quarterly investment income for its fiscal second quarter, driven by yield compression and weaker cash flow dynamics across its structured credit holdings.

TG Therapeutics (NASDAQ:TGTX) reported positive topline results from an early-stage clinical evaluation of a subcutaneous formulation of its flagship therapy, BRIUMVI, in patients with myasthenia gravis, marking a significant milestone in the company’s strategy to expand the drug's utility beyond its approved indication for multiple sclerosis.

RedHill Biopharma (NASDAQ:RDHL) announced that the U.S. Food and Drug Administration has granted rare pediatric disease designation to its investigational asset, opaganib, for the treatment of neuroblastoma, a type of cancer that primarily affects infants and young children.

Invivyd (NASDAQ:IVVD) has initiated dosing in its LIBERTY Phase 3 clinical trial, a randomized, double-blind study designed to evaluate the safety, tolerability, and immunology of its investigational monoclonal antibody candidate, VYD2311, alone and co-administered with an mRNA COVID-19 vaccine in healthy adults.

Alterity Therapeutics (NASDAQ:ATHE) has successfully concluded an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), securing critical regulatory alignment on the design of its upcoming pivotal Phase 3 clinical program for lead candidate ATH434.